When will pemigatinib be included in medical insurance?

Pemigatinib (Pemigatinib) is approved to treat adults with cholangiocarcinoma that has spread or cannot be removed with surgery. n>Patients with FGFR2 gene fusions or other changes in the FGFR2 gene structure, and myeloid or lymphoid cancers that have relapsed or failed to respond to treatment andhave certain changes in the FGFR1 gene structure. This use is approved under the FDA's accelerated approval program. The recommended dose is Taking it orally every day13.5 mg for 14 consecutive days, and then stopping treatment for 7 days, with a cycle of 21 days. In March 2022, pemetinib was approved by the State Food and Drug Administration for marketing in China. The specific time to enter medical insurance requires the drug to pass the relevant policies of the National Medical Insurance Bureau. Patients can consult the local Medical Insurance Bureau and other places.